Related Experiment Video
Updated: Aug 5, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
Functional Characterization and Inhibition Analysis of a Glutathione Transferase from Cryptosporidium parvum: A
Panagiota D Pantiora1, Nikolaos D Georgakis1, Dimitris Matiadis2
1Laboratory of Enzyme Technology, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, 75 Iera Odos Street, 11855 Athens, Greece.
Insights
Researchers identified a unique glutathione transferase (GST) in Cryptosporidium parvum, a potential drug target. This enzyme
Area of Science:
- Parasitology
- Biochemistry
- Drug Discovery
Background:
- Cryptosporidiosis, caused by Cryptosporidium parvum, is a major diarrheal illness.
- Current treatments for cryptosporidiosis are limited, necessitating new therapeutic strategies.
Purpose of the Study:
- To clone, express, and functionally characterize a glutathione transferase (GST) from Cryptosporidium parvum (CpGST).
- To evaluate CpGST as a potential drug target for treating cryptosporidiosis.
Main Methods:
- Biocomputing analysis and structural modeling of CpGST.
- Expression of CpGST in E. coli and enzymatic characterization.
- Inhibition assays using polyphenols and curcumin analogues.
Main Results:
- CpGST exhibits distinct structural features and a non-canonical thioredoxin fold compared to human homologs.
- The enzyme shows catalytic activity with standard GST substrates but limited substrate affinity.
- Polyphenols and curcumin analogues are potent inhibitors of CpGST, with mixed-type inhibition.
Conclusions:
- CpGST is a structurally and functionally distinct enzyme, adapted to parasite metabolism.
- CpGST's divergence from human GSTs and its druggability make it a promising target for anti-cryptosporidial drug development.
- Targeting CpGST could disrupt parasite stress response and detoxification pathways.
Abstract:
Background/Objectives: Cryptosporidiosis, caused by Cryptosporidium parvum, is a significant cause of diarrheal disease, particularly affecting young children and immunocompromised individuals. With current treatments offering limited efficacy, there is an urgent need for novel therapeutic targets. Methods: In this study, we report the cloning, expression, and functional characterization of a glutathione transferase (GST) from C. parvum (CpGST). Results: Biocomputing analysis revealed a single gene encoding a cytosolic enzyme with distinct structural features, compared to human cytosolic homologs. Structural modeling indicated a non-canonical thioredoxin fold and a truncated C-terminal domain, suggesting functional divergence. CpGST was expressed in Escherichia coli, and its enzymatic properties were characterized. Although the enzyme displayed a narrow substrate spectrum, it showed a distinct substrate preference, retaining catalytic activity toward the standard GST substrates 1-chloro-2,4-dinitrobenzene (CDNB) and cumene hydroperoxide (CuOOH). Steady-state kinetic analysis revealed limited affinity for both reduced glutathione (GSH) and CDNB. Inhibition analysis identified several polyphenols and synthetic curcumin analogues as potent inhibitors, with IC50 values in the low micromolar range. Kinetic analysis with the most potent inhibitor revealed a mixed-type inhibition mechanism. Conclusions: These findings support the classification of CpGST as a structurally and functionally distinct member of the GST family, likely adapted to the parasite's physiology and metabolism. The enzyme's divergence from human GSTs, along with its favorable druggability profile, underscores its potential as a target for anti-cryptosporidial drug development, particularly in strategies aimed at disrupting stress response and detoxification pathways.
More Related Videos
09:13Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
Published on: November 22, 2024
08:48In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Related Concept Videos
Antiprotozoal Agents
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Anthelminthic Agents